Rhythm Pharmaceuticals announced that its drug Imcivree failed to meet primary endpoints in a Phase 3 clinical trial for treating rare, genetically-driven obesity. The MC4R agonist did not demonstrate significant weight reduction in enrolled patients, according to Endpoints News.
The trial failure represents a significant setback for Rhythm as the company approaches a major regulatory approval deadline. Imcivree targets a specific pathway involved in appetite regulation and weight control in patients with rare genetic forms of obesity.